In the past decade, scientific research on immune regulation has exploded thanks to the re-emergence of T
suppressor cells (Ts), now coined “regulatory T cells” (Tregs). It is now clear that there are many different
populations of Tregs, and that they play major roles in the control of immune responses. As the induction and effector mechanisms
used by regulatory T cells are being unraveled, new opportunities are emerging for immune intervention in cancer, autoimmune
disease, allergy, and in the induction of clinical transplantation tolerance. This conference will discuss the most up-to-date
information on the development, function, mechanism of action, and homeostasis of regulatory T cells, and their translation
to the clinic. Several presentations will highlight current strategies to manipulate regulatory T cells as individualized
medicine in preclinical studies and the results of clinical trials in various human diseases.
Aim of Conference
Upon completion of this meeting, participants should be able:
- To update the latest development of regulatory T cells and their clinical application in human diseases including
diabetes, GVHD, allergy, cancer, transplantation tolerance.
- To introduce Chinese medical community one of the most cutting-edge topics in medicine.
- To foster the development of scientific exchange and cooperation between China and Western countries.
- To discuss what is known about the molecular/biochemical pathways utilized by regulatory T cells in suppression
of cellular activation in vitro and in vivo, and discuss their potential targets in detail.
- To compare the immune function of the thymic-derived regulatory T cells with other important, but distinct,
T cell populations.
- To discuss the potential mechanisms for modulation of regulatory T cell function in autoimmune diseases,
allergy, transplantation tolerance, infectious disease and tumor immunity including the status of clinical trials.
|The Forbidden City